ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 893

Association Between Human Leukocyte Antigen-B’s Amino Acid Variation and Disease-Susceptibility To Takayasu’s Arteritis

Hajime Yoshifuji1, Chikashi Terao2, Kosaku Murakami3, Daisuke Kawabata3, Koichiro Ohmura1, Takao Fujii4, Yasushi Kawaguchi5, Hisashi Yamanaka5 and Tsuneyo Mimori1, 1Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, 2Center for Genomic Medicine, Kyoto University, Kyoto, Japan, 3Dept of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, 4Department of the Control for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan, 5Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Behcet's syndrome, Takayasu.s arteritis and human leukocyte antigens (HLA)

  • Tweet
  • Email
  • Print
Session Information

Title: Vasculitis I

Session Type: Abstract Submissions (ACR)

Background/Purpose: HLA-B52 and HLA-B51 are frequently seen in Asian population and are almost identical except two amino acid residues(the 63rd and 67th), but HLA-B52 is related with susceptibility to Takayasu’s arteritis (TAK) while HLA-B51 is related with susceptibility to Behçet’s disease.   To understand the mechanisms, we analyzed the variation of HLA-B amino acid sequences in TAK patients.

Methods: We collected DNA of 173 TAK patients from Kyoto University Hospital and Tokyo Women’s Medical University Hospital, genotyped their HLA-B alleles, and compared them with those of 2000 healthy controls.

Results: HLA-B52 was strongly related with TAK susceptibility (P < 0.000000000000001), while HLA-B51 was not (P = 0.39).   Analysis of HLA-B’s amino acid variations revealed that 171H (histidine at 171st position) compared with 171Y was a risk factor (P < 0.00000001), and 67F compared with 67notF (S, Y, C or M) was a protective factor (P < 0.0001) of TAK susceptibility.   Both the 171st and 67th amino acids are located at the groove of HLA-B protein, implying immune response is related to the pathogenesis.   Both HLA-B52 and HLA-B51 have the TAK-susceptible 171H.    While HLA-B52 has the TAK-susceptible 67S, HLA-B51 has the protective 67F.   That is a plausible reason why HLA-B51 was not related with TAK susceptibility.   Besides, we also searched for single nucleotide polymorphisms (SNPs) of non-HLA genes that related to TAK susceptibility and found several candidates of genes.

Conclusion: The difference of HLA-B’s 67th amino acid residue was supposed to divide the susceptibilities to TAK or Behçet’s disease.   Further analyses are needed to know what kind of peptides show affinities to the HLA-B’s groove.


Disclosure:

H. Yoshifuji,
None;

C. Terao,
None;

K. Murakami,
None;

D. Kawabata,
None;

K. Ohmura,
None;

T. Fujii,
None;

Y. Kawaguchi,
None;

H. Yamanaka,
None;

T. Mimori,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/association-between-human-leukocyte-antigen-bs-amino-acid-variation-and-disease-susceptibility-to-takayasus-arteritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology